Intercept Pharmaceuticals, Inc. Logo
Featured events
Date Event Details  
Mar 20–21, 2015
AASLD Industry Colloquium: Novel Targets and Therapies in Liver Disease
Location: Hilton Durham Research Triangle Park

The Industry Colloquium will provide a unique and rare opportunity for interactions between Industry and liver disease experts. Seeking to help identify unmet needs in hepatology, this one and one-half day conference will look toward the future to determine how to address the long-term challenges that hepatologists are likely to face in the coming years.


Industry Advisory Panel

  • John G. McHutchison, MD, FAASLD
  • David A. Shapiro, MD
  • Teresa L. Wright, MD, FAASLD
  • Nathaniel A. Brown, MD
  • Juan Carlos Lopez-Talavera, MD, PhD
  • Nikolai V. Naoumov, MD, FAASLD

To identify unmet needs in liver disease therapy

Learning Objectives

  • Examine unmet needs in the treatment of liver disease
  • Identify new targets and therapies in liver disease
  • Review and facilitate new drug development and approval

Target Audience
Industry R&D and commercial application staff, academic scientists and clinicians

Hilton Durham Research Triangle Park, North Carolina


Mar 20, 2015
6:00 PM ET
Intercept Research Analyst and Investor Meeting

Research Analyst and Investor Event on March 20, 2015

New subgroup analyses from the Phase 2b FLINT trial of obeticholic acid (OCA) in patients with nonalcoholic steatohepatitis (NASH) will be presented at a poster session at the American Association for the Study of Liver Disease (AASLD) Industry Colloquium for Novel Targets and Therapies in Liver Disease on March 20, 2015 in Durham, North Carolina. Intercept management will host an event for analysts and investors after the market close on Friday, March 20, 2015 to discuss these subgroup analyses.

Obeticholic Acid For The Treatment Of NASH: Efficacy In High-Risk Patients

Obeticholic Acid For The Treatment Of NASH: Characterization Of Effects On Cardiometabolic Parameters

Participant International Dial-In Number: (315) 625-6894
Participant Toll-Free Dial-In Number: (855) 232-3919
Conference ID 6408058

This is not an official event/function of the American Association for the Study of Liver Diseases.


Upcoming events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Date Title
Archived event
Date Event Details
Mar 3, 2015
11:20 AM
Intercept to Present at Cowen Healthcare Conference
Speaker: Mark Pruzanski, M.D., CEO
= add file to Briefcase